The role of fractalkine (CX3CL1) in regulation of CD4+ cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis

Clinical Immunology

Volumn 157, Issue 2, 2015, Pages 121-132

  Blauth, Kevin ^a   Zhang, Xin ^a   Chopra, Manisha ^a   Rogan, Sarah ^a   Markovic Plese, Silva ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

CX3CL1; CX3CR1; ICAM 1; IFN ; Multiple sclerosis; TNF

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, HUMAN; CX3CR1 PROTEIN, HUMAN; ICAM1 PROTEIN, HUMAN; MESSENGER RNA;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; BRAIN REGION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELL SURFACE; CEREBROSPINAL FLUID; CHEMOTAXIS ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN SECRETION; RECURRENT DISEASE; REMISSION; UPREGULATION; CASE CONTROL STUDY; CELL MOTION; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASE; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SECRETION (PROCESS);

ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; CHEMOKINE CX3CL1; DEMYELINATING DISEASES; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, CHEMOKINE; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924183386     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.01.001     Document Type: Article

References (50)

1. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6:1167-1175.
2. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 1994, 179:973-984.
3. Broux B., Pannemans K., Zhang X., Markovic-Plese S., Broekmans T., Eijnde B.O., et al. CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. J. Autoimmun. 2012, 38:10-19.
4. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
5. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.A., et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997, 387:611-617.
6. Tsou C.L., Haskell C.A., Charo I.F. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem. 2001, 276:44622-44626.
7. Chapman G.A., Moores K., Harrison D., Campbell C.A., Stewart B.R., Strijbos P.J. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci. 2000, 20:RC87.
8. Kastenbauer S., Koedel U., Wick M., Kieseier B.C., Hartung H.P., Pfister H.W. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J. Neuroimmunol. 2003, 137:210-217.
9. Matsumiya T., Imaizumi T., Fujimoto K., Cui X., Shibata T., Tamo W., et al. Soluble interleukin-6 receptor alpha inhibits the cytokine-induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp. Cell Res. 2001, 269:35-41.
10. Nakayama T., Watanabe Y., Oiso N., Higuchi T., Shigeta A., Mizuguchi N., et al. Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1. J. Immunol. 2010, 185:6472-6479.
11. Meucci O., Fatatis A., Simen A.A., Miller R.J. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8075-8080.
12. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
13. Foussat A., Coulomb-L'Hermine A., Gosling J., Krzysiek R., Durand-Gasselin I., Schall T., et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur. J. Immunol. 2000, 30:87-97.
14. Barlic J., McDermott D.H., Merrell M.N., Gonzales J., Via L.E., Murphy P.M. Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms. J. Biol. Chem. 2004, 279:48520-48534.
15. Ramos M.V., Fernandez G.C., Brando R.J., Panek C.A., Bentancor L.V., Landoni V.I., et al. Interleukin-10 and interferon-gamma modulate surface expression of fractalkine-receptor (CX(3)CR1) via PI3K in monocytes. Immunology 2010, 129:600-609.
16. Haskell C.A., Cleary M.D., Charo I.F. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J. Biol. Chem. 1999, 274:10053-10058.
17. Fraticelli P., Sironi M., Bianchi G., D'Ambrosio D., Albanesi C., Stoppacciaro A., et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 2001, 107:1173-1181.
18. Yoneda O., Imai T., Nishimura M., Miyaji M., Mimori T., Okazaki T., et al. Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur. J. Immunol. 2003, 33:53-58.
19. Ancuta P., Wang J., Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J. Leukoc. Biol. 2006, 80:1156-1164.
20. Yang X.P., Mattagajasingh S., Su S., Chen G., Cai Z., Fox-Talbot K., et al. Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway. Circ. Res. 2007, 101:1001-1008.
21. Dustin M.L., Rothlein R., Bhan A.K., Dinarello C.A., Springer T.A. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 1986, 137:245-254.
22. Rothlein R., Dustin M.L., Marlin S.D., Springer T.A. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 1986, 137:1270-1274.
23. Bullard D.C., Hu X., Schoeb T.R., Collins R.G., Beaudet A.L., Barnum S.R. Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:851-857.
24. Fabry Z., Waldschmidt M.M., Hendrickson D., Keiner J., Love-Homan L., Takei F., et al. Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55. J. Neuroimmunol. 1992, 36:1-11.
25. Greenwood J., Etienne-Manneville S., Adamson P., Couraud P.O. Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier. Vasc. Pharmacol. 2002, 38:315-322.
26. Willems F., Marchant A., Delville J.P., Gerard C., Delvaux A., Velu T., et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 1994, 24:1007-1009.
27. Tsakadze N.L., Sithu S.D., Sen U., English W.R., Murphy G., D'Souza S.E. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J. Biol. Chem. 2006, 281:3157-3164.
28. Trojano M., Avolio C., Liuzzi G.M., Ruggieri M., Defazio G., Liguori M., et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999, 53:1402-1408.
29. Rieckmann P., Michel U., Albrecht M., Bruck W., Wockel L., Felgenhauer K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J. Neuroimmunol. 1995, 60:9-15.
30. Polman C.H., Reingold S.C., Banwell B., Clanet M., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
31. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343:898-904.
32. Meeker R.B., Poulton W., Markovic-Plese S., Hall C., Robertson K. Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection. J. Neurovirol. 2011, 17:258-273.
33. Simpson J., Rezaie P., Newcombe J., Cuzner M.L., Male D., Woodroofe M.N. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J. Neuroimmunol. 2000, 108:192-200.
34. Balashov K.E., Rottman J.B., Weiner H.L., Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6873-6878.
35. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
36. Olsson B., Ridell B., Carlsson L., Jacobsson S., Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008, 112:1078-1084.
37. Shamri R., Grabovsky V., Gauguet J.M., Feigelson S., Manevich E., Kolanus W., et al. Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat. Immunol. 2005, 6:497-506.
38. Pelfrey C.M., Trotter J.L., Tranquill L.R., McFarland H.F. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients. J. Neuroimmunol. 1993, 46:33-42.
39. Pette M., Fujita K., Kitze B., Whitaker J.N., Albert E., Kappos L., et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990, 40:1770-1776.
40. Markovic-Plese S., Fukaura H., Zhang J., al-Sabbagh A., al-Southwood S., Sette A., et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J. Immunol. 1995, 155:982-992.
41. Kim H.B., Kim C.K., Iijima K., Kobayashi T., Kita H. Protein microarray analysis in patients with asthma: elevation of the chemokine PARC/CCL18 in sputum. Chest 2009, 135:295-302.
42. Vazquez-Martin A., Colomer R., Menendez J.A. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur. J. Cancer 2007, 43:1117-1124.
43. Markovic-Plese S., Cortese I., Wandinger K.P., McFarland H.F., Martin R. CD4+CD28- costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 2001, 108:1185-1194.
44. D'Haese J.G., Demir I.E., Friess H., Ceyhan G.O. Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin. Ther. Targets 2010, 14:207-219.
45. Ridderstad Wollberg A., Ericsson-Dahlstrand A., Jureus A., Ekerot P., Simon S., Nilsson M., et al. Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:5409-5414.
46. Nanki T., Urasaki Y., Imai T., Nishimura M., Muramoto K., Kubota T., et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J. Immunol. 2004, 173:7010-7016.
47. Huang D., Shi F.D., Jung S., Pien G.C., Wang J., Salazar-Mather T.P., et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006, 20:896-905.
48. Garcia J.A., Pino P.A., Mizutani M., Cardona S.M., Charo I.F., Ransohoff R.M., et al. Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. J. Immunol. 2013, 191:1063-1072.
49. Haskell C.A., Hancock W.W., Salant D.J., Gao W., Csizmadia V., Peters W., et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J. Clin. Invest. 2001, 108:679-688.
50. Mizuno T., Kawanokuchi J., Numata K., Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003, 979:65-70.